A phase 2b randomized, controlled, partially blinded clinical trial to investigate the safety, efficacy and dose-response of BMS-986001 in treatment –naïve HIV-1 infected subjects, followed by an open-label period on the recommended dose

Double Blind through Week 24. Partially Blind (to subjects, caregivers, Investigators) through Week 48.

Presentation: HIV NRTI BMS-986001 in Antiretroviral-Naïve Subjects: Week 24/48 Analyses. [Oral Abstract: H-642] 54th ICAAC, September 5-9, 2014 at Washington DC, USA